12:00 AM
 | 
Mar 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xalkori crizotinib regulatory update

Pfizer said China's State Food and Drug Administration (SFDA) approved an NDA for Xalkori crizotinib to treat locally advanced or metastatic non-small cell lung cancer (NSCLC)...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >